Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Glucagon, an essential regulator of glucose homeostasis, also modulates lipid metabolism and promotes weight loss, as reflected by the wasting observed in glucagonoma patients. Recently, coagonist peptides that include glucagon agonism have emerged as promising therapeutic candidates for the treatment of obesity and diabetes. We developed a novel stable and soluble glucagon receptor (GcgR) agonist, which allowed for in vivo dissection of glucagon action. As expected, chronic GcgR agonism in mice resulted in hyperglycemia and lower body fat and plasma cholesterol. Notably, GcgR activation also raised hepatic expression and circulating levels of fibroblast growth factor 21 (FGF21). This effect was retained in isolated primary hepatocytes from wild-type (WT) mice, but not GcgR knockout mice. We confirmed this link in healthy human volunteers, where injection of natural glucagon increased plasma FGF21 within hours. Functional relevance was evidenced in mice with genetic deletion of FGF21, where GcgR activation failed to induce the body weight loss and lipid metabolism changes observed in WT mice. Taken together, these data reveal for the first time that glucagon controls glucose, energy, and lipid metabolism at least in part via FGF21-dependent pathways.
Overview
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Previous studies have shown that chronic GCG receptor agonism increased circulating FGF21 in mice and acute glucagon administration transiently increased FGF21 levels in humans25.”
From Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial (2024) · cites this paper as [25]
Citations
Cites
1 retracted
Berglund, E. D., Kang, L., Lee-Young, R. S., Hasenour, C. M., Lustig, D. G., Lynes, S. E., Donahue, E. P., Swift, L. L., Charron, M. J., & Wasserman, D. H. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00263.2010 · Cited by 100
RetractedFGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125 · cited 1×
“Recent studies suggest that, like glucagon, FGF21 signaling regulates glucose, lipid, cholesterol, and bile acid metabolism (14,15), implicating FGF21 as an attractive drug candidate for metabolic disease.”
BackgroundSelf-citationInagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495
Disorders of motility and muscle tone with special reference to the corpus striatum
Wilson, S. A. K. (1925) · The Lancet · Cited by 1,409
Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151
Fibroblast Growth Factor 21 Corrects Obesity in Mice
Coskun, T., Bina, H. A., Schneider, M. A., Dunbar, J. D., Hu, C. C., Chen, Y., Moller, D. E., & Kharitonenkov, A. (2008) · Endocrinology · doi:10.1210/en.2008-0816 · Cited by 1,031
Self-citationThe metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21
Kharitonenkov, A., Wroblewski, V. J., Koester, A., Chen, Y.-F., Clutinger, C. K., Tigno, X. T., Hansen, B. C., Shanafelt, A. B., & Etgen, G. J. (2007) · Endocrinology · doi:10.1210/en.2006-1168 · Cited by 738 · cited 2×
“FGF21 pharmacology reduces hyperglycemia, dyslipidemia, and plasma glucagon in diabetic mice and nonhuman primates (9).”
BackgroundSelf-citationA new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Self-citationα-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Gromada, J., Franklin, I., & Wollheim, C. B. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0007 · Cited by 581
Mallinson, C. N., Bloom, S. R., Warin, A. P., Salmon, P. R., & Cox, B. (1974) · The Lancet · doi:10.1016/s0140-6736(74)91343-9 · Cited by 505
Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., et al. (2009) · Diabetes · doi:10.2337/db09-0278 · Cited by 409
The metabolic actions of glucagon revisited
Habegger, K. M., Heppner, K. M., Geary, N., Bartness, T. J., DiMarchi, R., & Tschöp, M. H. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.187 · Cited by 406 · cited 2×
“Chronic GcgR agonism potentiates hepatic and adipocyte lipolysis while reducing plasma cholesterol (23).”
BackgroundResultSelf-citationPPARα is a key regulator of hepatic FGF21
Lundåsen, T., Hunt, M. C., Nilsson, L.-M., Sanyal, S., Angelin, B., Alexson, S. E. H., & Rudling, M. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.06.068 · Cited by 383
Dunning, B. E., & Gerich, J. E. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0026 · Cited by 369
Hotta, Y., Nakamura, H., Konishi, M., Murata, Y., Takagi, H., Matsumura, S., Inoue, K., Fushiki, T., & Itoh, N. (2009) · Endocrinology · doi:10.1210/en.2009-0119 · Cited by 352 · cited 1×
“FGF21-deficient mice were generated as previously described (17) and maintained in our facilities on a C57Bl/6J (Jackson Laboratories) background.”
MethodSelf-citationLeptin therapy in insulin-deficient type I diabetes
Wang, M.-Y., Chen, L., Clark, G. O., Lee, Y., Stevens, R. D., Ilkayeva, O. R., Wenner, B. R., Bain, J. R., Charron, M. J., Newgard, C. B., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909422107 · Cited by 327
Berglund, E. D., Li, C. Y., Bina, H. A., Lynes, S. E., Michael, M. D., Shanafelt, A. B., Kharitonenkov, A., & Wasserman, D. H. (2009) · Endocrinology · doi:10.1210/en.2009-0221 · Cited by 297
Self-citationSarruf, D. A., Thaler, J. P., Morton, G. J., German, J., Fischer, J. D., Ogimoto, K., & Schwartz, M. W. (2010) · Diabetes · doi:10.2337/db09-1878 · Cited by 288
Impaired negative feedback suppression of bile acid synthesis in mice lacking βKlotho
Ito, S., Fujimori, T., Furuya, A., Satoh, J., Nabeshima, Y., & Nabeshima, Y.-I. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23076 · Cited by 248
Effect of Glucagon on Food Intake and Body Weight in Man
Schulman, J. L., Carleton, J. L., Whitney, G., & Whitehorn, J. C. (1957) · Journal of Applied Physiology · doi:10.1152/jappl.1957.11.3.419 · Cited by 174 · cited 1×
“Studies over the past five decades have reported glucagon-stimulated body weight loss in both humans (29) and rodents (30).”
BackgroundFGF21 reloaded: challenges of a rapidly growing field
Kharitonenkov, A., & Larsen, P. J. (2010) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2010.11.003 · Cited by 163 · cited 1×
“The metabolic action profile of FGF21, derived from the liver, pancreas, and adipose tissue (22), significantly overlaps with that of glucagon.”
BackgroundSelf-citationMu, J., Pinkstaff, J., Li, Z., Skidmore, L., Li, N., Myler, H., Dallas-Yang, Q., Putnam, A.-M., Yao, J., Bussell, S., et al. (2012) · Diabetes · doi:10.2337/db11-0838 · Cited by 162 · cited 1×
“These effects were accompanied by increased insulin secretion and sensitivity (32), building upon a prior body of work detailing the antidiabetic effects of FGF21 (9,33–36).”
BackgroundSelf-citationFormation and Structure of Gels and Fibrils from Glucagon
Beaven, G. H., Gratzer, W. B., & Davies, H. G. (1969) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1969.tb00735.x · Cited by 132 · cited 2×
“Although discovered in the early 1920s, the native structure of glucagon has hindered indepth investigation of its biology, as it does not easily lend itself to mechanistic pharmacological studies due to its low aqueous solubility (20) and its propensity to form amyloid-like fibrils (21).”
BackgroundDipeptidyl Peptidase IV (DPIV/CD26) Degradation of Glucagon
Hinke, S. A., Pospisilik, J. A., Demuth, H.-U., Mannhart, S., Kühn-Wache, K., Hoffmann, T., Nishimura, E., Pederson, R. A., & McIntosh, C. H. S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.6.3827 · Cited by 120
Gu, W., Yan, H., Winters, K. A., Komorowski, R., Vonderfecht, S. L., Atangan, L. I., Sivits, G. N., Hill, D., Yang, J., Bi, V., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.157685 · Cited by 109
Too Much Glucagon, Too Little Insulin
Brown, R. J., Sinaii, N., & Rother, K. I. (2008) · Diabetes Care · doi:10.2337/dc08-0575 · Cited by 106
Glucagon regulation of energy metabolism
Heppner, K. M., Habegger, K. M., Day, J. W., Pfluger, P. T., Pérez–Tilve, D., Ward, B., Gelfanov, V. M., Woods, S. C., DiMarchi, R. D., & Tschöp, M. H. (2010) · Physiology & Behavior · doi:10.1016/j.physbeh.2010.03.019 · Cited by 97 · cited 1×
“Though consistent with an increased overall EE (23,24), our findings are in direct conflict with a prior report (31) and, as such, deserve continued investigation.”
ResultSelf-citationALFORD, F. P., BLOOM, S. R., & NABARRo, J. D. N. (1976) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-42-5-830 · Cited by 74 · cited 1×
“Reports from humans and dogs suggest that the half-life of this hormone is 5–6 min (26,27).”
BackgroundInsulin and glucagon as determinants of body weight set point and microregulation in rats
de Castro, J. M., Paullin, S. K., & DeLugas, G. M. (1978) · Journal of Comparative and Physiological Psychology · doi:10.1037/h0077485 · Cited by 74
Quesada, I., Todorova, M. G., & Soria, B. (2006) · Biophysical Journal · doi:10.1529/biophysj.105.069906 · Cited by 71
Jaspan, J. B., Polonsky, K. S., Lewis, M., Pensler, J., Pugh, W., Moossa, A. R., & Rubenstein, A. H. (1981) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1981.240.3.e233 · Cited by 68 · cited 2×
“The liver and kidneys rapidly clear circulating native glucagon (25,26).”
BackgroundCaloric Restriction Chronically Impairs Metabolic Programming in Mice
Kirchner, H., Hofmann, S. M., Fischer-Rosinský, A., Hembree, J., Abplanalp, W., Ottaway, N., Donelan, E., Krishna, R., Woods, S. C., Müller, T. D., et al. (2012) · Diabetes · doi:10.2337/db11-1621 · Cited by 44 · cited 1×
“a combined indirect calorimetry system (TSE Systems, Chesterfield, MO) as previously described (18).”
MethodSelf-citationGuo, Y., Jolly, R. A., Halstead, B. W., Baker, T. K., Stutz, J. P., Huffman, M., Calley, J. N., West, A., Gao, H., Searfoss, G. H., et al. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfm009 · Cited by 36 · cited 1×
“Primary hepatocytes were isolated as previously described (19).”
MethodGlucagon Suppression of Ghrelin Secretion Is Exerted at Hypothalamus-Pituitary Level
Arafat, A. M., Perschel, F. H., Otto, B., Weickert, M. O., Rochlitz, H., Schöfl, C., Spranger, J., Möhlig, M., & Pfeiffer, A. F. H. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0225 · Cited by 35 · cited 1×
“The test was performed as detailed previously (16).”
MethodSelf-citationEffects of iodination on the distribution of peptide hormones in aqueous two-phase polymer systems
Desbuquois, B., & Aurbach, G. D. (1974) · Biochemical Journal · doi:10.1042/bj1430083 · Cited by 16 · cited 2×
“Although discovered in the early 1920s, the native structure of glucagon has hindered indepth investigation of its biology, as it does not easily lend itself to mechanistic pharmacological studies due to its low aqueous solubility (20) and its propensity to form amyloid-like fibrils (21).”
BackgroundEdwards, P. A., Lan, S. F., & Fogelman, A. M. (1988) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38821-0 · Cited by 10 · cited 4×
“Although we observed decreased HMGCR in WT mice, it is important to note that the decreased cholesterolemia in WT mice was not observed in mice lacking FGF21.”
BackgroundInfluentialMorawska, D., Sieklucka-Dziuba, M., & Kleinrok, Z. (1998) · PubMed · Cited by 8
Cited by
Energy Metabolism in the Liver
Rui, L. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130024 · Cited by 1,953
Metabolism disrupting chemicals and metabolic disorders
Heindel, J. J., Blumberg, B., Cave, M., Machtinger, R., Mantovani, A., Mendez, M. A., Nadal, A., Palanza, P., Panzica, G., Sargis, R., et al. (2017) · Reproductive Toxicology · doi:10.1016/j.reprotox.2016.10.001 · Cited by 1,101
Understanding the Physiology of FGF21
Fisher, F. M., & Maratos-Flier, E. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105339 · Cited by 912
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696
Self-citationA rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
Self-citation
Metadata
- Authors
- Habegger, K. M., Stemmer, K., Cheng, C., Müller, T. D., Heppner, K. M., Ottaway, N., Holland, J., Hembree, J. L., Smiley, D., Gelfanov, V., Krishna, R., Arafat, A. M., Konkar, A., Belli, S., Kapps, M., Woods, S. C., Hofmann, S. M., D’Alessio, D., Pfluger, P. T., Perez-Tilve, D., Seeley, R. J., Konishi, M., Itoh, N., Kharitonenkov, A., Spranger, J., DiMarchi, R. D., & Tschöp, M. H.
- Affiliations
- University of Cincinnati (US)
- Helmholtz Munich (DE)
- Eli Lilly (United States) (US)
- Indiana University Bloomington (US)
- Charité – Universitätsmedizin Berlin (DE)
- F. Hoffmann-La Roche AG (CH)
- Metabolic Disease Institute, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Cincinnati, Cincinnati, Ohio
- Kyoto University (JP)
- Corresponding author
- Tschöp, Matthias H.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2013-04-16
- Volume
- 62
- Issue
- 5
- Pages
- 1453-1463
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3636653
- OpenAlex
- W2131192628
- Cited by
- 245
- References
- 38
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 21 · 2023: 15 · 2022: 17 · 2021: 19 · 2020: 16 · 2019: 16 · 2018: 17 · 2017: 18 · 2016: 22 · 2015: 27 · 2014: 22 · 2013: 12
- FWCI
- 12.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- OPUS (Augsburg University) (submittedVersion, cc-by-nc-nd)
- Funders
- American Diabetes Association
- Eli Lilly and Company
- F. Hoffmann-La Roche
- University of Cincinnati
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- FGF21, glucagon, glucagon receptor agonist, glucose homeostasis, lipid metabolism, weight loss, hyperglycemia, obesity, serum cholesterol, energy metabolism
- MeSH terms
- Adult, Animals, Cells, Cultured, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Fibroblast Growth Factors, Glucagon, Humans, Hypoglycemic Agents, Insulin Resistance, Male, Mice, Mutant Strains, Obesity, Peptides, Recombinant Proteins, Receptors, Glucagon, Mice, Knockout, Cross-Over Studies, Anti-Obesity Agents, Hepatocytes, Mice, Rats, HEK293 Cells, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.